| |
Control group
|
Intervention group
|
P
|
|---|
|
Sex
| |
%(n)
| | |
0.75a
|
| |
Women
| |
68.7 (121)
|
59.2(103)
| |
| |
Men
| |
31.3(55)
|
40.8(71)
| |
| |
Overall
| |
100(176)
|
100.0(174)
| |
|
Mean ± SD
| | | |
|
Age (years)
|
83.3 ± 6.9
|
80.8 ± 7.3
|
0.001b
|
|
Weight (kg)
|
65.5 ± 12.1
|
66.8 ± 12.0
|
0.335b
|
|
Height (m)
|
1.6 ± 0.1
|
1.6 ± 0.1
|
0.069b
|
|
BMI (Kg/m2)
|
26.1 ± 4.0
|
26.3 ± 3.8
|
0.721b
|
|
SBP (mm Hg)
|
130.7 ± 17.3
|
134.7 ± 18.7
|
0.060b
|
|
DBP (mm Hg)
|
71.5 ± 11.3
|
75.0 ± 12.3
|
0.012b
|
|
Creatinine (mg/dl)
|
1.1 ± 0.4
|
1.2 ± 0.8
|
0.052b
|
|
Body surface (m2)
|
1.7 ± 0.2
|
1.7 ± 0.2
|
0.162b
|
|
GFR (ml/min/1.73 m2)
|
61.7 ± 16.5
|
60.7 ± 17.0
|
0.572b
|
|
CrCl (ml/min)
|
45.0 ± 12.1
|
45. + ±13.0
|
0.525b
|
|
CrCl-BS (ml/min/1.73 m2)
|
46.3 ± 11.6
|
47.1 ± 12.6
|
0.550b
|
|
Total number of drugs per patient
|
7.3 ± 2.9
|
6.3 ± 3.2
|
0.003b
|
|
Drugs with restriction in RI per patient
|
4.0 ± 2.0
|
3.5 ± 2.1
|
0.069b
|
|
Number of DRP per patient
|
0.7 ± 1.0
|
0.5 ± 1.0
|
0.164b
|
|
Prevalence of DI (%)
|
17.5 ± 28.2
|
15.5 ± 29.1
|
0.514b
|
|
Comorbidity %(n)
| | | |
|
Hypertension
|
72.2(127)
|
69.5(121)
|
0.639a
|
|
T2DM
|
23.9(42)
|
11.5(20)
|
0.003a
|
|
Dyslipidemia
|
39.8(70)
|
37.4(65)
|
0.662a
|
|
Hyper/Hypo Thyroidism
|
5.7(10)
|
6.3(11)
|
0.826a
|
|
CVD
|
30.7(54)
|
23.6(41)
|
0.150a
|
|
CKD
|
10.2(18)
|
8.0(14)
|
0.579a
|
- Abbreviations: BMI Body Mass Index, SBP Systolic Blood Pressure, DBP, Diastolic Blood Pressure, T2DM Type 2 Diabetes Mellitus, CVD Cardiovascular Disease, CKD Chronic Kidney Disease, GFR Rate of Glomerular filtration, CrCl Creatinine Clearance, CrCl-BS Creatinine Clearace adjusted to body surface, RI renal impairment, DRP Drug-related problem, DI Dosing inadequacy, Drugs with restrictions (dose adjustment needed in case of renal impairment (RI)) per patient [20–22], SD Standard deviation.
-
aχ2Test.
-
b T Student test for independent groups.
